

FITC anti-human CD3 Antibody

Catalog# / Size	317305 / 25 tests 317306 / 100 tests
Clone	OKT3
Regulatory Status	RUO
Workshop	HCDM listed
Other Names	T3, CD3ε
Isotype	Mouse IgG2a, κ
Description	CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details

Verified Reactivity	Human
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser	Blue Laser (488 nm)
Application Notes	The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHL1.⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

- Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
- Barclay N, *et al.* 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
- Li B, *et al.* 2005. *Immunology* 116:487.
- Jeong HY, *et al.* 2008. *J. Leucocyte Biol.* 83:755. [PubMed](#)
- Alter G, *et al.* 2008. *J. Virol.* 82:9668. [PubMed](#)
- Manevich-Mendelson E, *et al.* 2009. *Blood* 114:2344. [PubMed](#)
- Pinto JP, *et al.* 2010. *Immunology.* 130:217. [PubMed](#)

9. Biggs MJ, *et al.* 2011. *J. R. Soc. Interface.* 8:1462. [PubMed](#)

Product Citations

1. Afolabi LO, *et al.* 2021. *Front Immunol.* 12:701671. [PubMed](#)
2. Guo X, *et al.* 2016. *Mol Ther Methods Clin Dev.* 3:15054. [PubMed](#)
3. Zitti B, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-10403-0. [PubMed](#)
4. Lugo-Reyes SO, *et al.* 2021. *J Clin Immunol.* 41:1291. [PubMed](#)
5. Hess NJ, *et al.* 2020. *J Immunol.* 205:272. [PubMed](#)
6. Want MY, *et al.* 2019. *Oncoimmunology.* 8:e1586042. [PubMed](#)
7. Clayton K, *et al.* 2014. *J Immunol.* 192:782. [PubMed](#)
8. Shi Z, *et al.* 2021. *Ann Clin Transl Neurol.* 8:43. [PubMed](#)
9. Catapano M, *et al.* 2020. *J Invest Dermatol.* 140:816. [PubMed](#)
10. Wu X, *et al.* 2020. *Cancers (Basel).* 12:. [PubMed](#)
11. Moen IN, *et al.* 2021. *Cell Death Discov.* 7:36. [PubMed](#)
12. Wang Y, *et al.* 2019. *J Transl Med.* 17:93. [PubMed](#)
13. Yamada E, *et al.* 2021. *Gut Microbes.* 13:1997292. [PubMed](#)
14. Zhang B, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
15. Dai Q, *et al.* 2020. *Front Immunol.* 11:539654. [PubMed](#)
16. Sun Y, *et al.* 2022. *Nat Commun.* 13:3916. [PubMed](#)
17. Zhang Z, *et al.* 2021. *Acta Pharm Sin B.* 11:1965. [PubMed](#)
18. Celik H, *et al.* 2021. *Cancer Discov.* 11:3126. [PubMed](#)
19. Lin L, *et al.* 2018. *Oncol Lett.* 16:1259. [PubMed](#)
20. Fujigaki J, *et al.* 2015. *PLoS One.* 10: 0132521. [PubMed](#)
21. Giesecke C, *et al.* 2017. *Cytometry A.* 10.1002/cyto.a.23250. [PubMed](#)
22. Gillissen MA, *et al.* 2018. *Blood.* 131:131. [PubMed](#)
23. Sperk M, *et al.* 2021. *iScience.* 24:102111. [PubMed](#)
24. Nakasone H, *et al.* 2021. *Commun Biol.* 4:1177. [PubMed](#)
25. Wu X, *et al.* 2021. *Front Immunol.* 12:731767. [PubMed](#)
26. Jeyanathan M, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
27. Omer OS, *et al.* 2020. *Methods Mol Biol.* 2121:199. [PubMed](#)
28. James KR, *et al.* 2020. *Nat Immunol.* 1.113194444. [PubMed](#)
29. Kim K, *et al.* 2019. *Nat Microbiol.* 1.586111111. [PubMed](#)
30. Hazenberg MD, *et al.* 2019. *Blood Adv.* 2.659722222. [PubMed](#)
31. Chulpanova DS, *et al.* 2021. *Biology (Basel).* 10:. [PubMed](#)
32. Golebski K, *et al.* 2021. *Immunity.* 54(2):291-307.e7. [PubMed](#)
33. Oyer JL, *et al.* 2022. *Front Immunol.* 13:861681. [PubMed](#)
34. Zhang CR, *et al.* 2022. *Blood Cancer Discov.* 3:220. [PubMed](#)
35. Agashe VV, *et al.* 2018. *J Immunol.* 201:772. [PubMed](#)
36. Cheng J, *et al.* 2022. *iScience.* 25:103588. [PubMed](#)
37. Tsai H, *et al.* 2021. *EMBO Mol Med.* 13:e12834. [PubMed](#)
38. Zhang W, *et al.* 2022. *J Transl Med.* 20:558. [PubMed](#)
39. Aagaard K, *et al.* 2017. *Sci Rep.* 7:41389. [PubMed](#)
40. Miyamae Y, *et al.* 2020. *Cell Chemical Biology.* 27(12):1573-1581.e3. [PubMed](#)
41. Winkler C, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
42. Akusjärvi SS, *et al.* 2022. *iScience.* 25:103607. [PubMed](#)
43. Zhou Z, *et al.* 2022. *J Gastrointest Oncol.* 13:732. [PubMed](#)
44. Zhao B, *et al.* 2013. *PLoS One.* 8:77708. [PubMed](#)
45. Bal S, *et al.* 2016. *Nat Immunol.* 10.1038/ni.3444. [PubMed](#)
46. Gopalakrishnapillai A, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
47. Loo Yau H, *et al.* 2021. *STAR Protocols.* 2(2):100549. [PubMed](#)
48. Shikhagaie M, *et al.* 2017. *Cell Rep.* 18(7):1761-1773. [PubMed](#)
49. Svensson Akusjärvi S, *et al.* 2022. *Commun Biol.* 5:357. [PubMed](#)
50. Fierle JK, *et al.* 2021. *Cell Reports Medicine.* 2(8):100362. [PubMed](#)
51. Sullivan KD *et al.* 2016. *eLife.* 5 pii: e16220. [PubMed](#)
52. Ochi T, *et al.* 2011. *Blood.* 118:1495. [PubMed](#)

RRID

AB_571906 (BioLegend Cat. No. 317305)

AB_571907 (BioLegend Cat. No. 317306)

Antigen Details

Structure	Ig superfamily, the subunits CD3 γ , CD3 δ , CD3 ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution	Mature T and NK T cells, thymocyte differentiation
Function	Antigen recognition, signal transduction, T cell activation
Ligand/Receptor	Peptide antigen bound to MHC
Cell Type	NKT cells, T cells, Thymocytes, Tregs
Biology Area	Immunology
Molecular Family	CD Molecules

Antigen References

1. Barclay N, *et al.* 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, *et al.* 1981. *Eur. J. Immunol.* 11:329.
3. Lanier L, *et al.* 1986. *J. Immunol.* 137:2501.

Gene ID

[916](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Purified anti-human CD3, FITC anti-human CD3, PE anti-human CD3, Alexa Fluor® 488 anti-human CD3, Alexa Fluor® 647 anti-human CD3, Pacific Blue™ anti-human CD3, APC anti-human CD3, Biotin anti-human CD3, Brilliant Violet 605™ anti-human CD3, Brilliant Violet 650™ anti-human CD3, Ultra-LEAF™ Purified anti-human CD3, Brilliant Violet 711™ anti-human CD3, Brilliant Violet 785™ anti-human CD3, Brilliant Violet 510™ anti-human CD3, PE/Cyanine7 anti-human CD3, PerCP/Cyanine5.5 anti-human CD3, PerCP anti-human CD3, Alexa Fluor® 700 anti-human CD3, APC/Cyanine7 anti-human CD3, Brilliant Violet 421™ anti-human CD3, PE/Dazzle™ 594 anti-human CD3, APC/Fire™ 750 anti-human CD3, GMP Ultra-LEAF™ Purified anti-human CD3 SF, PE/Cyanine5 anti-human CD3 Antibody

Product Data



Human peripheral blood lymphocytes stained with OKT3 FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587